Evaluation of dysfunctional high-density lipoprotein levels with myeloperoxidase/paraoxonase-1 ratio in rheumatoid arthritis

Alisik T., Alisik M., Nacir B., Ayhan F. F. , Genc H., EREL Ö.

International Journal of Clinical Practice, 2021 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume:
  • Publication Date: 2021
  • Doi Number: 10.1111/ijcp.14172
  • Title of Journal : International Journal of Clinical Practice


© 2021 John Wiley & Sons LtdBackground: The aim of this study is to evaluate dysfunctional high-density lipoprotein cholesterol (HDL) by measuring myeloperoxidase (MPO)/paraoxonase 1 (PON1) ratio in patients with rheumatoid arthritis (RA) and to investigate the relationship between dysfunctional HDL and cardiovascular disease (CVD) in RA patients. Methods: Sixty-seven healthy individuals and 130 RA patients were included in the study. Routine lipid panels (triglyceride (TG), low-density lipoprotein cholesterol (LDL), HDL, total cholesterol (TC), PON1 and MPO levels were measured. Disease activity scores-28 (DAS28) of RA patients were calculated. Cardiological examination records of the patients were assessed to detect patients who also have CVD. Results: There were no significant differences between RA and control groups in routine lipid profiles (P >.05 for all). MPO/PON1 ratios were significantly elevated in the RA group compared with the control group (P <.001). MPO/PON1 ratios were higher in RA patients with CVD history compared with those without CVD (P <.05). MPO/PON1 ratios were correlated with DAS28 scores (rho: 0.357, P <.001). Conclusion: HDL dysfunction determined by the MPO/PON1 ratio may be associated with the pathophysiology of increased CVD in RA. Thus, evaluating dysfunctional HDL levels by measuring the MPO/PON1 ratio in RA patients may allow more detailed patient follow-up, as well as the reduction of CVD events in RA patients with therapeutic agents aiming to increase the functional properties of HDL by decreasing this ratio.